CLONING AND EXPRESSION OF FULL LENGTH HUMAN ORFS

描述：(申请人的描述)基因克隆和表达是 使技术能够将基因组学与功能基因组学联系起来。 它们结合在一起，使科学家能够将遗传信息从 基因组转化为蛋白质，生命的功能单位。Invitgen的 克隆和表达载体类似于操作系统 通过细胞将遗传信息转化为功能单位 硬件。我们最近开发了一种自动克隆和 围绕我们的几项专利构建的表达系统和独家 许可证。我们将使用这个系统将全长的人类cDNA克隆到 一种能够进行功能鉴定的哺乳动物表达载体 基因产物。应用计划和研究计划将分开 分成三个不同的重点领域。产生的全长人类cDNA 通过在这些重点领域采用的每一项战略，将复制 转化为表达载体，测序，并在CHO细胞中表达 验证完整性。该研究计划旨在将重点放在全面- 现有数据库中的长度序列以指导模板组装和 基于RT-PCR的首次获得全长模板的策略 水平策略，然后利用现有的EST同源标准来 优先获取与癌症相关的未知5‘末端 CDNA 建议的商业应用： 克隆的癌症相关基因的营销将涉及一项战略 迅速将第一个也是最大的系列推向市场- 在表达载体(和其他载体)中对癌症相关基因进行长度测定。营销 在这些基因中，将包括Invitgen的所有促进因素 策略，例如： 1.在科学期刊和出版物上刊登广告 2.在Invitgen的时事通讯Expression中发表文章 (每年6期) 3.通过互联网访问可搜索的克隆基因数据库 4.向行业内的目标受众发送定向宣传邮件 和学术界 5.公共关系和新闻稿 6.展销会 7.科学研讨会和讲习班

DESCRIPTION: (Applicant's Description) Gene cloning and expression are enabling technologies linking genomics to functional genomics. Together, they allow scientists to convent the genetic information from a genome into proteins, the functional units of life. Invitrogen's cloning and expression vectors are similar to an operating system for conversion of genetic information into functional units via cellular hardware. We have recently developed an automated cloning and expression system built around several of our patents and exclusive licenses. We will use this system to clone full-length human cDNAs into a mammalian expression vector to allow functional characterization of the gene products. The application and research plan will be divided into 3 separate areas of focus. The full-length human cDNAs generated by each of the strategies employed in these focus areas will be cloned into expression plasmids, sequenced, and expressed in CHO cells to verify integrity. The research plan is designed to focus on the full- length sequences in existing databases to guide template assembly and RT-PCR-based strategies of full-length template acquisition as a first- level strategy, and then utilize the existing EST homology criteria to prioritize the acquisition of the unknown 5' ends of cancer-related CDNAs PROPOSED COMMERCIAL APPLICATION: Marketing of the cloned cancer-related genes will involve a strategy of quickly bringing to market the first and largest collection the full- length cancer-related genes in expression (and other) vectors. Marketing of these genes will include the full range of Invitrogen's promotional tactics such as: 1. Advertisements in scientific journals and publications 2. Publication of articles in Invitrogen's newsletter Expressions (6 issues annually) 3. Internet access to a searchable database of cloned genes 4. Directed promotional mailings to target audiences in industry and academia 5. Public relations and press releases 6. Trade shows 7. Scientific seminars, and workshops